June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates a Continued Reduction in the Mean Rate of Geographic Atrophy Growth: 18-Month Results from the GATHER1 Clinical Trial
Author Affiliations & Notes
  • Veeral Sheth
    University Retina, Illinois, United States
  • Footnotes
    Commercial Relationships   Veeral Sheth, Iveric Bio (C)
  • Footnotes
    Support  Iveric Bio
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 333. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Veeral Sheth; Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates a Continued Reduction in the Mean Rate of Geographic Atrophy Growth: 18-Month Results from the GATHER1 Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2021;62(8):333.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Avacincaptad pegol, a polyethylene glycol-conjugated oligonucleotide, is a potent C5 inhibitor delivered via a 100 µl intravitreal injection. The 18-month results of GATHER1, a randomized, double-masked, multi-national, sham-controlled clinical trial evaluating avacincaptad pegol for treatment of geographic atrophy (GA) secondary to age-related macular degeneration, are reported here.

Methods : Patients were randomized to avacincaptad pegol 1 mg, avacincaptad pegol 2 mg, avacincaptad pegol 4 mg or sham injection. GA progression was evaluated as a change in GA lesion area over 18 months measured by fundus autofluorescence; square-root transformation was applied to mitigate the impact of baseline factors on GA growth. Other assessments included visual function (best-corrected visual acuity and low-luminance visual acuity) and safety analysis.

Results : The least-squares mean change from baseline to month 18 in square-root GA lesion area was 0.599 mm in sham-treated patients vs 0.430 mm in avacincaptad pegol 2 mg-treated patients (28% reduction; p<0.0014). The least-squares mean change from baseline to month 18 in square-root GA lesion area was 0.559 mm in sham-treated patients vs 0.391 mm in avacincaptad pegol 4 mg-treated patients (30% reduction; p<0.0021). There were no significant differences in best-corrected visual acuity or low-luminance visual acuity between avacincaptad and sham-treated patients. Avacincaptad pegol was generally well tolerated after 18 months of administration, with no drug-related adverse events or trial discontinuations.

Conclusions : Intravitreal avacincaptad pegol resulted in a decrease in the rate of GA lesion growth over 18 months of treatment versus sham injection. GATHER2, a second pivotal clinical trial comparing avacincaptad 2 mg vs sham, has been initiated and is currently enrolling patients.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×